投资建议：国内检测需求短期下滑，海外有望成为新增长点。我们预计公司2025-2027 年实现营业收入 21.22/25.76/31.99 亿元， 归母净利润2.53/3.16/4.04 亿元。对应PE 分别为36.7/29.4/23.0 倍，维持"增 持"评级。 化学发光装机顺利，流水线业务快速发展：2025 年上半年，公司自产化学发光仪器新增装机1,090 台， 其中国内新增装机546 台，其中单机600 速的化学发光仪器新增装机占比为46.70%；海外新增装机544 台，流水线新增装机57 条，同比增长54.05%，其中公司自研自产流水线iTLA Max 新增签约11 条。 持续研发投入，完善化学发光检测产品：2025 年上半年，公司研发投入1.43 亿元，新增获批化学发光 检测试剂国内1注4册项证，包括血栓 4 项、乙肝定量3 项、骨代谢2 项、甲功、性激素、自免肝、高血 压、炎症等新产品，进一步完善化学发光检测产品。 事件：2025 年上半年，公司实现营收8.08 亿元，同比下降15.79%；实现归母净利润2,626.93 万元，同 比下降84.82%；2Q2025 公司实现营收3.91亿元，同比下滑 ...

Core Viewpoint - The company reported a decline in net profit for 2024 and Q1 2025, primarily due to fair value losses, while maintaining growth in its core business segments and optimizing its product offerings [1][2]. Financial Performance - In 2024, the company achieved revenue of 2.012 billion yuan, with a net profit of 302 million yuan, representing a decrease of 15.06%. The non-recurring net profit was 287 million yuan, an increase of 30.84% [1]. - For Q1 2025, the company reported revenue of 418 million yuan, a decrease of 3.13%, and a net profit of 10 million yuan, down 84.64% [1]. Business Structure and Growth - The company’s non-COVID core business generated revenue of 1.672 billion yuan in 2024, up 26.13%, with domestic revenue of 1.422 billion yuan (+21.14%) and overseas revenue of 250 million yuan (+64.78%) [2]. - The gross margin for 2024 was 65.28%, an increase of 8.47 percentage points, attributed to revenue growth and improved revenue structure [2]. Product and Market Development - The chemical luminescence business saw revenue of 1.522 billion yuan in 2024, a growth of 30.27%, with 2,662 new installations [3]. - As of Q1 2025, the chemical luminescence business generated revenue of 314 million yuan (+2.35%), with overseas revenue increasing by 56.31% [3]. Research and Development - The company invested 338 million yuan in R&D in 2024, accounting for 16.80% of revenue, while Q1 2025 R&D investment was 67 million yuan, representing 16.08% of revenue [4]. - The company received domestic and international certifications for new products, enhancing its product solutions [4]. Investment Outlook - The company is positioned as a leading player in the chemical luminescence sector, with rapid market penetration in specialized projects driving reagent business growth [5]. - The forecast for net profit from 2025 to 2027 is adjusted to 341 million yuan, 427 million yuan, and 526 million yuan, with respective growth rates of 13.01%, 25.18%, and 23.28% [5].

Summary of the Conference Call for 亚辉龙 Company Overview - **Company**: 亚辉龙 (YHLO) - **Industry**: In Vitro Diagnostics (IVD) Key Financial Performance - **2024 Total Revenue**: 1.772 billion CNY, up 26.13% YoY - **2025 Q1 Revenue**: 418 million CNY, down 3.13% YoY - **Non-COVID Related Revenue (2024)**: 1.672 billion CNY, up 24.11% YoY - **Non-COVID Related Revenue (2025 Q1)**: 345 million CNY, up 1.09% YoY - **Overseas Non-COVID Related Revenue Growth**: 64.78% in 2024, 46.53% in 2025 Q1 [2][3] Profitability Metrics - **2024 Gross Margin**: 65.15%, up 8.58 percentage points YoY - **2025 Q1 Gross Margin**: 58.87%, down 2.9 percentage points YoY - **Chemical Luminescence Reagent Gross Margin**: 81.75% in 2024, down 1.2 percentage points YoY [2][5] Expense Management - **2024 Sales Expenses**: Increased by 9.94% - **2024 R&D Expenses**: Increased by 6.16%, R&D expense ratio at 16.74% - **2025 Q1 Sales Expenses**: Increased by 52% - **2025 Q1 Management Expenses**: Increased by 176% - **2025 Q1 R&D Expenses**: Decreased by 20.78% [2][6] Product Performance - **Automated Chemical Luminescence Immunoassay Analyzer Revenue (2024)**: 1.522 billion CNY, up 30.27% - **Overseas Revenue for Analyzers**: Increased by 69.1% [2][7] Installation and Market Coverage - **2024 New Installations of Self-produced Analyzers**: 2,662 units, with overseas growth of 80.56% - **Total Installations by 2025 Q1**: Over 11,340 units - **Coverage of Medical Institutions**: Over 6,090 domestic medical institutions, with a 70% coverage rate in top-tier hospitals [3][10][8] Innovations and R&D - **AI Medical Innovations**: Development of an AI-based indirect immunofluorescence ANA interpretation system with 91.3% accuracy and a false negative rate below 0.3% [12][13] - **Diabetes Management Platform**: Collaboration with Jiangsu Provincial People's Hospital to enhance diabetes diagnosis efficiency [14] Market Challenges and Strategies - **IVD Industry Pressures**: Challenges from DRG implementation, inspection mutual recognition, and healthcare cost control policies [17] - **Response to DRG Policy**: Adjusting strategies to maintain stable growth despite reduced testing volumes [18][19] Future Outlook - **Overseas Business Growth**: Expected to maintain over 50% growth in 2025 Q1, with a focus on non-US markets [15][36] - **Long-term Goals**: Aim to become a leading domestic brand in the immunodiagnostics field within five years and a global leader in ten years [38] Regulatory and Market Dynamics - **Impact of Tariff Policies**: Potential for increased domestic brand adoption due to tariff impacts on imports [20][30] - **Drug Centralized Procurement**: Implementation across provinces, providing opportunities for domestic brands [31] Conclusion - **Strategic Focus**: Emphasis on innovation, market expansion, and maintaining competitive advantages through AI and product development in the IVD sector [21][22][24]

Core Viewpoint - The company demonstrated strong operational resilience in its 2024 annual report, achieving a revenue of 2.012 billion yuan and a net profit of 302 million yuan, with a significant year-on-year growth in its self-owned business segment [2] Group 1: Financial Performance - The company reported a revenue of 2.012 billion yuan for 2024, with a net profit attributable to shareholders of 302 million yuan and a non-recurring net profit of 287 million yuan [2] - Revenue from the self-owned business segment reached 1.672 billion yuan, marking a year-on-year increase of 26.13% [2] Group 2: R&D and Technological Advancements - The company invested 338 million yuan in R&D for 2024, representing a year-on-year increase of 3.84% and accounting for 16.80% of total revenue [2] - The company has established a humanized antibody technology platform and integrated AI into the development of bioactive raw materials [3] Group 3: Product Development and Market Expansion - The company added 15 new chemical luminescence testing reagent projects, bringing the total to 178 registered projects by the end of the reporting period [3] - In the first quarter of 2025, the company added 6 more projects, increasing the total to 184 [3] - The company achieved a revenue of 250 million yuan from overseas self-owned business, reflecting a year-on-year growth of 64.78% [3] Group 4: Automation and Smart Solutions - The company developed the iTLA Max laboratory automation system, which integrates AI technology and can process up to 1,200 sample tubes per hour [3] - The automation system connects various instruments and utilizes intelligent robots for automatic supply addition [3] Group 5: International Market Performance - In the first quarter of 2025, the company added 283 new installations overseas, representing a year-on-year increase of 92.52% [3] - The overseas market generated a revenue of 52.3813 million yuan from chemical luminescence business, showing a year-on-year growth of 56.31% [3]